TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Capstone Therapeutics ( (CAPS) ) has issued an announcement.
Capstone Holding Corp. has entered into a securities purchase agreement with an institutional investor, authorizing the issuance of senior secured convertible notes with an original principal amount of up to $10,909,885. On November 28, 2025, the company and the buyer agreed to reduce the conversion price of the July 2025 Convertible Note to $0.75 for the remaining principal amount of $500,744.01, and for $1,772,856.21 of the October 2025 Convertible Note, potentially impacting the company’s stock conversion strategy.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.83 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, negative equity, and ongoing losses. Technical analysis suggests bearish momentum, with the stock trading below key moving averages. Valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield, further weighing on the stock’s appeal.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 901,285
Technical Sentiment Signal: Sell
Current Market Cap: $7.12M
For detailed information about CAPS stock, go to TipRanks’ Stock Analysis page.